{"classes":[{"categories":[{"measurements":[{"comment":"The upper confidence interval was not assessable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"6.4","upperLimit":"NA","value":"15.5"},{"comment":"The upper confidence interval was not assessable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"10.1","upperLimit":"NA","value":"22.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"A secondary efficacy endpoint is DOR by central IRR. The DOR is defined as the time from the date that a confirmed response per modified RECIST Version 1.1/PCWG3 is first reported to the time that progressive disease (PD) is first documented. Progressive disease is defined using RECIST v1.1, as at least a 20% increase in the sum of the diameters of target lesions, or an unequivocal increase in non-target lesions, or the appearance of new lesions. PCWG3 criteria is used to document evidence of disease progression in bone lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA (breast cancer susceptibility gene) mutation detected in their tumor.","id":"OG000","title":"BRCA Mutation"},{"description":"Patients with other deleterious HRR (homologous recombination repair) gene mutation detected in their tumor.","id":"OG001","title":"Other Gene Mutation"}],"paramType":"MEDIAN","populationDescription":"Patients with a confirmed response in the IRR Efficacy Population. The IRR efficacy population is defined by measurable disease status at baseline using modified RECIST Version 1.1 criteria per independent radiology review. Note, there were no patients with confirmed response by IRR in the ATM, CDK12 and CHEK2 arms.","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.","title":"Duration of Response (DOR) by Gene in Patients With Confirmed Response Per Central Independent Radiology Review (IRR)","type":"SECONDARY","unitOfMeasure":"months"}